Renal disease associated with chronic myeloproliferative neoplasms.
Lucijanic M, Krecak I, Kusec R.
Expert Rev Hematol. 2022 Feb;15(2):93-96. doi: 10.1080/17474086.2022.2039117. Epub 2022 Feb 9.
[Myeloproliferative neoplasms and chronic inflammatory bowel disease].
Hesselø H, Bak M, Boysen T, Bytzer P, Hasselbalch HC.
Ugeskr Laeger. 2020 May 5;182(22):V09190483.
Chronic myeloproliferative diseases.
de Lacerda JF, Oliveira SN, Ferro JM.
Handb Clin Neurol. 2014;120:1073-81. doi: 10.1016/B978-0-7020-4087-0.00072-3.
Chronic myeloproliferative disorders--introduction.
Skoda R, Prchal JT.
Semin Hematol. 2005 Oct;42(4):181-3. doi: 10.1053/j.seminhematol.2005.08.004.
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A, Alkhateeb H, Gangat N.
Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.
Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.
Khan M, Sarfraz M, Daver N.
Future Oncol. 2017 Jan;13(2):117-120. doi: 10.2217/fon-2016-0310. Epub 2016 Sep 27.
[New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO, Ocias LF, Kallenbach K, Kjær L, Kristensen TK, Pallisgaard N, Petersen BL, Skov V, de Stricker K, Larsen TS, Hasselbalch HC.
Ugeskr Laeger. 2015 May 4;177(19):V12140653.
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S.
Cells. 2021 Dec 16;10(12):3551. doi: 10.3390/cells10123551.
Bone morbidity in chronic myeloproliferative neoplasms.
Farmer S, Ocias LF, Vestergaard H, Broesby-Olsen S, Hermann AP, Frederiksen H.
Expert Rev Hematol. 2015 Aug;8(4):447-56. doi: 10.1586/17474086.2015.1053456. Epub 2015 Jun 2.
[Chronic myeloproliferative syndromes].
de Ozalla CB, García Suárez J.
Rev Clin Esp. 1999 Apr;199 Suppl 1:28-36.
